News | March 06, 2009

Minority Patients Less Likely to Receive Treatment for Advanced Heart Failure

March 6, 2009 – New research published in the March edition of the HeartRhythm Journal reveals that black and Hispanic patients who were eligible for cardiac resynchronization therapy with defibrillator (CRT-D) were less likely to receive therapy than eligible white patients.

The study also found that both minority groups were more likely to meet established criteria and white patients were more likely to receive CRT-D outside of published guidelines. The new study is the first of its kind to examine and compare Hispanic, white and black patients within a national study population.

The national study examined 108,341 participants in more than 1,000 hospitals enrolled in the National Cardiovascular Data Registry (NCDR) from January 2005 through April 2007. The NCDR ICD Registry, developed in collaboration with the American College of Cardiology and the Heart Rhythm Society, was examined for racial and ethnic disparities in CRT-D implantation.

Lead author Steven A. Farmer, M.D., Cardiovascular Division at the Hospital of the University of Pennsylvania in Philadelphia, reviewed the data and the number of patients who met established guidelines. Of the 108,341 registry participants:

- 22,205 patients met guidelines to receive an ICD or CRT-D
- 27,165 patients received CRT-D therapy, more than the actual number of people who were eligible.

Results conclude that CRT-eligible black and Hispanic patients were less likely to receive CRT-D than were white patients. A substantial proportion of patients received CRT-D outside of published guidelines, although black and Hispanic patients were more likely to meet all eligibility criteria.

“These results reinforce a number of questions about how race and ethnicity can impact who receives advanced treatment for heart failure,” Dr. Farmer stated. “It is very surprising that there are a significant number of ICD patients who meet the required criteria for CRT-D and are not receiving the therapy, while many patients who receive the treatment fail to meet those same guidelines.”

For more information: www.heartrhythmjournal.com.

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init